946826-43-3Relevant articles and documents
Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold
Lv, Xiao,Yang, Xiaoxiao,Zhan, Mei-Miao,Cao, Peichang,Zheng, Shihong,Peng, Ruijun,Han, Jihong,Xie, Zhouling,Tu, Zhengchao,Liao, Chenzhong
supporting information, (2019/10/19)
Polo-like kinase 1 (Plk1) is a validated target for the treatment of cancer. In this report, by analyzing amino acid residue differences among the ATP-binding pockets of Plk1, Plk2 and Plk3, novel selective Plk1 inhibitors were designed based on BI 2536 a